ISRCTN86135778 https://doi.org/10.1186/ISRCTN86135778

Comparative analysis of adult-onset Still's disease (AOSD) treatments

Submission date
12/12/2023

Recruitment status
No longer recruiting

Registration date
14/12/2023

Overall study status
Completed

Last Edited
14/12/2023

Condition category
Musculoskeletal Diseases

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[ ] Results
[ ] Individual participant data
[ ] Record updated in last year

Plain English summary of protocol

Background and study aims
Adult-onset Still’s disease (AOSD) is a rare autoinflammatory disorder with increased mortality. Complications such as macrophage activation syndrome in continuously active disease carry a high mortality risk. Glucocorticoids (GC) and conventional disease-modifying antirheumatic drugs (DMARDs) are commonly used as first-line therapeutic options as opposed to recently licensed interleukin-1 (IL1)-receptor antagonist anakinra (ANA), neutralizing IL1b-antibody canakinumab (CAN), or non-licensed use of IL-6 receptor antibody tocilizumab (TCZ). However, DMARDs have a considerably slower onset, and GC may result in substantial side-effects such as diabetes mellitus or osteonecrosis of the hips. Our study evaluates potential benefits of biologicals (ANA, CAN, TCZ) as first-line therapeutic options in AOSD.

Who can participate?
Data from AOSD-patients (disease onset) fulfilling the Yamaguchi classification criteria, over 18 years, female/male or divers of the last 15 years of participating centers are included in the study.

What does the study involve?
We plan to retrospectively analyze data from German rheumatology centers (last 15 years), examining both the effectiveness of therapy (percentage of patients in remission) and side effects of different therapies.

What are the possible benefits and risks of participating?
Participating in this study offers the benefit of contributing valuable data to guide treatment decisions for AOSD patients, including insights into treatment responses and potential complications under various treatment options.

Where is the study run from?

When is the study starting and how long is it expected to run for?
January 2023 to January 2024

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr. A. Kernder, anna_kernder@t-online.de

Contact information

Type(s)
Principal Investigator

Contact name
Prof Stefan Vordenbäumen

ORCID ID
http://orcid.org/0000-0001-5725-5483

Contact details
Hauptstr. 74-76
Meerbusch
Germany
40668
+49 21 50 / 9 17-0
info@rrz-meerbusch.de

Type(s)
Public, Scientific

Contact name
Dr Anna Kernder

ORCID ID
http://orcid.org/0000-0002-7742-7526

Contact details
Moorenstraße 5
Düsseldorf
Germany
40225
+49 02118100
anna_kernder@t-online.de

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers
Nil known

Study information

Scientific Title
Comparison of different treatments in adult-onset Still's disease (AOSD): biologics, glucocorticoids, and conventional disease-modifying antirheumatic drugs (DMARDs)

Acronym
TAST

Study objectives
Complication free remission rates are lower in patients initially treated with biological therapy as opposed to DMARD therapy

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 13/09/2023, Ethics Committee of the medical faculty of the University of Duesseldorf (Moorenstr. 5, Düsseldorf, 40225, Germany; +49 211 81-19591; ethikkommission@med.uni-duesseldorf.de), ref: 2023-2423

Study design
Retrospective chart review of AOSD patients from multiple German centers

Primary study design
Observational

Secondary study design
Cohort study

Study setting(s)
Hospital, Laboratory, Medical and other records

Study type(s)
Treatment

Participant information sheet
Not applicable (retrospective study)

Health condition(s) or problem(s) studied
Treatments of Adult-onset Still's Disease (AOSD, rheumatic disease)

Interventions
Retrospective Observational study

Data collected:
- Epidemiological data (age at onset, sex, height, weight, comorbidities)
- Disease activity data (items of the Pouchot Score, CRP, Ferritin, Leukocyte count, alternatively the EULAR-DAVID score if available in the meantime)
- Physician subjective evaluation of “remission” based on chart review
- fever yes/no
- arthritis yes/no
- ASOD-associated rash yes/no
- Treatment
- Complication of GC use:
Diabetes necessitating insulin therapy Gain in body weight (≥ 10%) Osteonecrosis of any joint
Psychosis or other psychiatric disease requiring psychopharmacological intervention
Hypertension
Dyslipidemia requiring therapy with e.g. statins
Worsening of bone density > 0,5 SD (T1-4, neck or total hip)
Clinical diagnosis of steroid myopathy Skin disease attributed to GC
Eye disease attributable to
- Serious infection necessitating intravenous antibiotic use
- Death
- Macrophage activation syndrome
- AOSD-associated pneumonitis
- ASOD-associated perimyocarditis
- Ongoing disease activity requiring switch from DMARD-based to biological therapy

Intervention Type
Other

Primary outcome measure
Sustained remission (definition see below) at week 12 and complication free until week 72 (definition see below).

For remission, all of the below must be fulfilled:
1. Physician subjective evaluation of “remission” based on chart review
2. CRP below 10 mg/l
3. No fever during last week
4. No arthritis during last week
5. No ASOD-associated rash during last week

For Complication-free (none of the following should have been appeared):
1. Complications of GC use
2. Diabetes necessitating insulin therapy
3. Gain in body weight (≥ 10%)
4. Osteonecrosis of any joint
5. Psychosis or other psychiatric disease requiring psychopharmacological intervention
6. Hypertension > 180 mmHg systolic pressure resulting in change of antihypertensive medication
7. Dyslipidemia requiring therapy with e.g. statins
8. Worsening of bone density > 0,5 SD (T1-4, neck or total hip), preexisting osteoporosis or osteoporosis diagnosed within 2 months of disease onset is not considered to be a GC-related event
9. Clinical diagnosis of steroid myopathy

10. Skin disease attributed to GC, e.g. striae, cutaneous necrosis, relevant subcutaneous bleeding or ulcerations
11. Eye disease attributable to GC (esp. cataract, glaucoma)
12. Serious infection necessitating intravenous antibiotic use
13. Death
14. Development of macrophage activation syndrome, AOSD-associated pneumonitis, ASOD-associated peri myocarditis
15. Ongoing disease activity requiring switch from DMARD-based to biological therapy

Secondary outcome measures
1. Flare-free survival in patients under remission
2. Rate of remission (definition see below) by week 12 and complication free by week 72
3. Retrospective analysis of differences in the glucocorticoid toxicity index (GTI)
4. GC dose reduction (at week 12 and week 72)
5. GC dose reduction by at least 75% compared to disease onset
6. Time to remission
7. Time to complication (definition see above)
8. Complications (definition see above)

Overall study start date
01/01/2023

Completion date
31/01/2024

Eligibility

Key inclusion criteria
1. Yamaguchi classification criteria are met
2. Documented clinical visits at onset/flare, by week 12 and week 72

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Sex
Both

Target number of participants
Required sample size per group: 50

Key exclusion criteria
Not matching the inclusion criteria

Date of first enrolment

15/09/2008

Date of final enrolment
31/01/2024

Locations

Countries of recruitment
Germany

Study participating centre
Rheinisches Rheuma-Zentrum St. Elisabeth-Hospital Meerbusch
Hauptstr. 74-76
Meerbusch-Lank
Germany
40668

Study participating centre
Klinik für Rheumatologie und Hiller Forschungszentrum, Uniklinik Düsseldorf, Medizinische Fakultät, Heinrich-Heine Universität
Moorenstraße 5
Düssseldorf
Germany
40225

Study participating centre
III Department of Medicine, University Medical Center Hamburg-Eppendorf
Martinistraße 52
Hamburg
Germany
20251

Study participating centre
Rheumazentrum Sachsen-Anhalt, Kooperationspartner der Otto-von-Guericke Universität Magdeburg, Helios Fachklinik Vogelsang-Gommern
Sophie-von-Boetticher-Str. 1
Vogelsang-Gommern
Germany
39245

Study participating centre

Medizinische Klinik 3 - Rheumatologie und Immunologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Ulmenweg 18
Erlangen
Germany
91054

Study participating centre
Medizinische Klinik 5, Sektion Rheumatologie, Universitätsklinikum Heidelberg
Voßstr. 2
Heidelberg
Germany
69120

Study participating centre
Medizinische Hochschule Hannover MHH
Carl-Neuberg-Str. 1
Hannover
Germany
30625

Study participating centre
Abt. Rheumatologie, klin. Immunologie, Osteologie und Physikalische Medizin, Campus Kerckhoff der Justus-Liebig-Universität Gießen
Benekestr. 2-8
Bad Nauheim
Germany
61231

Study participating centre
Universitätsklinikum Tübingen, Innere Medizin/Rheumatologie
Otfried-Müller-Strasse 10
Tübingen
Germany
72076

Study participating centre
Rheumazentrum Halle Universitätsmedizin Halle
Ernst-Grube-Straße 40

Halle
Germany
06120

Sponsor information

Organisation
St. Elisabeth-Hospital Meerbusch-Lank

Sponsor details
Department of Rheumatology
Meerbusch
Germany
40668
+49 21 50 / 9 17-0
Stefan.Vordenbaeumen@rrz-merbusch.de

Sponsor type
Hospital/treatment centre

Funder(s)

Funder type
Other

Funder Name
Investigator initiated and funded

Results and Publications

Publication and dissemination plan
Planned publication in a high-impact peer-reviewed journal

Intention to publish date
31/01/2025

Individual participant data (IPD) sharing plan
The raw data supporting the conclusions will be made available by the authors on reasonable request.
anna_kernder@t-online.de

IPD sharing plan summary

Available on request